Theseus Pharmaceuticals Inc

NASDAQ THRX

Data sourced from

and

Download Data

Theseus Pharmaceuticals Inc Free Cash Flow to Firm (FCFF) 5 year CAGR for the quarter ending March 31, 2023

Theseus Pharmaceuticals Inc Free Cash Flow to Firm (FCFF) 5 year CAGR is NA for the quarter ending March 31, 2023. Free Cash Flow to Firm represents the cash flow available to all capital providers, including both equity and debt holders. It considers the tax shield effect of interest expense. This ratio indicates the company's ability to generate cash flow available to all stakeholders, including interest payments to debt holders and returns to equity shareholders. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.

Theseus Pharmaceuticals Inc Free Cash Flow to Firm (FCFF) for the quarter ending September 30, 2022 was USD -6.18 M.

NASDAQ: THRX

Theseus Pharmaceuticals Inc

CEO	Dr. Iain D. Dukes D.Phil., DPHIL, M.A.
IPO Date	Oct. 7, 2021
Location	United States
Headquarters	245 Main Street, Cambridge, MA, United States, 02142
Employees	38
Sector	Healthcare
Industry	Biotechnology

Description

Theseus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. Its lead product candidate is THE-630, a pan-KIT inhibitor for the treatment of gastrointestinal stromal tumors. The company also develops THE-349, a fourth-generation selective epidermal growth factor receptor inhibitor to address C797X-mediated resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer. Its development programs address drug resistance mutations in key driver oncogenes, which are mutated genes that cause cancer. The company was incorporated in 2017 and is based in Cambridge, Massachusetts. As of February 14, 2024, Theseus Pharmaceuticals, Inc. operates as a subsidiary of Concentra Biosciences, LLC.

Key trends